| 摘要: |
| 目的分析急性B淋巴细胞白血病（B-ALL）患儿成纤维细胞生长因子受体3（FGFR3）基因的表达情况，探讨其在疾病预后判断中的意义。方法采用实时定量PCR法检测52例B-ALL患儿（B-ALL组）与12例对照儿童（对照组）骨髓血中B淋巴细胞FGFR3基因表达水平；并以B-ALL组患儿FGFR3基因表达水平的中位数为界，将B-ALL组患儿分为FGFR3基因高表达组和FGFR3基因低表达组。比较FGFR3基因高表达组和FGFR3基因低表达组患儿的各项临床指标；随访36个月，比较两组患儿的无事件生存（EFS）率。采用流式细胞术检测B淋巴细胞免疫分型、巢式PCR法检测B淋巴细胞融合基因，比较不同B淋巴细胞免疫分型及融合基因的B-ALL组患儿FGFR3基因表达水平。结果B-ALL组患儿FGFR3基因表达水平高于对照组儿童（1.637±0.903vs0.645±0.559，P＜0.05）。FGFR3基因高表达组与FGFR3基因低表达组患儿性别、年龄、外周血WBC、肝脾有无肿大、有无髓外浸润、B淋巴细胞免疫分型及染色体核型等临床指标比较均无统计学差异（均P＞0.05）。FGFR3基因高表达组患儿EFS率低于FGFR3基因低表达组患儿（49.97%vs76.17%，P＜0.05）。B-ALL组患儿中，CD34+患儿FGFR3基因表达水平高于CD34-患儿（P＜0.05），BCR/ABL+患儿FGFR3基因表达水平高于BCR/ABL-患儿（P＜0.05）。结论FGFR3基因高表达与肿瘤发生、发展有关，有望成为辅助评价儿童B-ALL预后的指标。 |
| 关键词: 急性 B 淋巴细胞白血病 FGFR3 预后 |
| DOI：10.12056/j.issn.1006-2785.2017.39.02.2015-1497 |
| 分类号: |
| 基金项目:浙江省自然科学基金资助项目（LQ12H08001）；浙江省医药卫生科技项目（2012KYB186）；宁波市自然科学基金项目（2012A610236）；宁波市医学科技计划项目（2011B23） |
|
| Expression of FGFR3 gene in childhood acute B lymphoblastic leukemia and its relation to disease progression |
|
WU Jingyi, ZHOU Jianfeng, PEI Renzhi, ZHANG Peisheng, LIU Xuhui, DU Xiaohong
|
|
Yinzhou Hospital，Medical College of Ningbo University
|
| Abstract: |
| Objective To investigate the expression of fibroblast growth factor receptors 3 (FGFR3) gene in childhood
acute B lymphoblastic leukemia (B-ALL), and its clinical significance in disease progression. Methods The expression levels of FGFR3 in 52 children with B-ALL and 12 normal children were assayed by real time RT-PCR. Clinical indicators were compared between patients with high FGFR3 expression and those with low FGFR3 expression. Patients were followed up for 36 months. The event-free survival (EFS) rate was compared with single factor analysis between two groups. B lymphocyte immune classification was detected by flow cytometry and B lymphocyte fusion gene was detected by nested PCR. The expression levels of FGFR3 were compared among different immune classification and fusion gene groups. Results FGFR3 was over-expressed in children with B-ALL compared with normal controls (1.637 ±0.903 vs 0.645 ±0.559, P ＜0.05). There were no significant differences in sex, age, peripheral blood WBC count, hepatosplenomegaly, extramedullary infiltration, B lymphocyte immune classification and karyotype between low FGFR3 group and high FGFR3 group (P ＞0.05). The probability of 3-year EFS for patients with high FGFR3 level was significantly lower than that with low FGFR3 level (49.97% vs 76.17%, P＜0.05). Expression levels of FGFR3 were significantly different between BCR/ABL+ group and BCR/ABL-group (P＜0.05) and between CD34+ group and CD34- group (P ＜0.05). Conclusion Over-expression of FGFR3 may participate in malignant hematopoiesis and the
detection of FGGR3 expression might be helpful in evaluation of disease progression in childhood acute B lymphoblasticleukemia. |
| Key words: Acute B lymphoblastic leukemia Fibroblast growth factor receptor 3 Progression |
